NEW YORK, NY / ACCESSWIRE / July 20, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Theratechnologies Inc.
https://ub.rdinvesting.com/news/?ticker=TH-TO
VBI Vaccines Inc.
https://ub.rdinvesting.com/news/?ticker=VBV-TO
Aralez Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=ARZ-TO
Evertz Technologies Limited
https://ub.rdinvesting.com/news/?ticker=IMV-TO
Theratechnologies Inc.'s stock moved 1.89% higher Wednesday, to close the day at $7.53. The stock recorded a trading volume of 137,966 shares, which was below its three months average volume of 172,579 shares. In the last year, Theratechnologies Inc.'s shares have traded in a range of 2.35 - 8.72. The share price has gained 220.43% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $7.76 is greater than its 200-day moving average of $5.72. Shares of Theratechnologies Inc. have gained approximately 174.82 percent year-to-date.
Access RDI's Theratechnologies Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=TH-TO
On Wednesday, shares in VBI Vaccines Inc. recorded a trading volume of 5,337 shares, which was above the three months average volume of 3,140 shares. The stock ended the day 1.16% lower at 5.98. The share price has gained 65.65% from its 52 week low with a 52 week trading range of 3.61 - 8.94.The company's shares are currently trading at their 200-day moving average. Moreover, the stock's 50-day moving average of $5.82 is below its 200-day moving average of $5.98. Shares of VBI Vaccines Inc. have gained approximately 44.1 percent year-to-date.
Access RDI's VBI Vaccines Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=VBV-TO
Aralez Pharmaceuticals Inc.'s stock moved 2.70% higher Wednesday, to close the day at $1.90. The stock recorded a trading volume of 42,965 shares, which was below its three months average volume of 49,749 shares. In the last year, Aralez Pharmaceuticals Inc.'s shares have traded in a range of 1.46 - 8.75. The share price has gained 30.14% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.72 is below its 200-day moving average of $3.32. Shares of Aralez Pharmaceuticals Inc. have fallen approximately 67.85 percent year-to-date.
Access RDI's Aralez Pharmaceuticals Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ARZ-TO
On Wednesday, shares in Immunovaccine Inc. recorded a trading volume of 110,775 shares, which was below the three months average volume of 156,951 shares. The stock ended the day 5.74% lower at 1.15. The share price has gained 125.49% from its 52 week low with a 52 week trading range of 0.51 - 1.70.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.23 is greater than its 200-day moving average of $1.16. Shares of Immunovaccine Inc. have gained approximately 69.12 percent year-to-date.
Access RDI's Immunovaccine Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=IMV-TO
Our Actionable Research on Theratechnologies Inc. (TSX:TH.TO), VBI Vaccines Inc. (TSX:VBV.TO), Aralez Pharmaceuticals Inc. (TSX:ARZ.TO) and Immunovaccine Inc. (TSX:IMV.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@rdinvesting.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com